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Objectives: Eumycetoma is currently treated with a combination of itraconazole therapy and surgery, with
limited success. Recently, olorofim, the lead candidate of the orotomides, a novel class of antifungal agents,
entered a Phase II trial for the treatment of invasive fungal infections. Here we determined the activity of oloro-
fim against Madurella mycetomatis, the main causative agent of eumycetoma.
Methods: Activity of olorofim against M. mycetomatis was determined by in silico comparison of the target gene,
dihydroorotate dehydrogenase (DHODH), and in vitro susceptibility testing. We also investigated the in vitro inter-
action between olorofim and itraconazole against M. mycetomatis.
Results: M. mycetomatis and Aspergillus fumigatus share six out of seven predicted binding residues in their
DHODH DNA sequence, predicting susceptibility to olorofim. Olorofim demonstrated excellent potency against
M. mycetomatis in vivo with MICs ranging from 0.004 to 0.125 mg/L and an MIC90 of 0.063 mg/L. Olorofim MICs
were mostly one dilution step lower than the itraconazole MICs. In vitro interaction studies demonstrated that
olorofim and itraconazole work indifferently when combined.
Conclusions: We demonstrated olorofim has potent in vitro activity against M. mycetomatis and should be
further evaluated in vivo as a treatment option for this disease.
Introduction
The poverty-associated disease mycetoma, which was added to
the Neglected Tropical Disease List in 2016 by WHO, remains a
major health problem in endemic areas.1,2 Most cases occur in the
mycetoma belt between latitudes 15 South and 30 North.3,4
Mycetoma presents itself as a subcutaneous chronic granuloma-
tous infectious and inflammatory disease characterized by the for-
mation of grains in affected tissues.3,5 In more than 80% of the
cases, the foot and leg are affected.4 This disease is divided into
two groups: actinomycetoma (mycetoma caused by bacteria)
and eumycetoma (mycetoma caused by fungi). Although many
different fungal species are found to cause eumycetoma,
Madurella mycetomatis dominates other fungal species and is pre-
sent in more than 70% of all patients.4,6
Eumycetoma is recalcitrant in nature, which necessitates pro-
longed antifungal therapy combined with massive and repeated
surgical debridement. In severe cases, amputation of the affected
part may be the only remaining treatment option.3,7,8 Previous
reports determined that M. mycetomatis was most susceptible to
the azole class of antifungal agents9–11 and is currently treated
with itraconazole.12 Treatment with itraconazole may take years
and, with an average monthly income of only $60/month, itracon-
azole at $330/month is considered to be too expensive for
patients. Thus there is a dire need for another antifungal agent
that is active against M. mycetomatis.13
Olorofim, formerly known as F901318 (F2G Ltd, Eccles,
Manchester, UK), is the leading representative from a novel
class of antifungal agents called the orotomides.14 Olorofim inhib-
its the fungal enzyme dihydroorotate dehydrogenase (DHODH)
leading to obstruction of the pyrimidine biosynthesis pathway.14,15
Studies have demonstrated that olorofim is active against patho-
genic and azole-resistant Aspergillus species,16–19 Scedosporium
species,20 Lomentospora prolificans,20 Coccidioides immitis,21
Fusarium proliferatum22 and other dimorphic fungi.22 Oliver et al.14
also demonstrated that olorofim exhibited much greater potency
against Aspergillus spp. compared with other leading antifungal
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classes. Given the potency and activity of olorofim, here we aim to
evaluate its in vitro activity against M. mycetomatis and the in vitro
interaction between olorofim and itraconazole as a first effort to
determine whether olorofim shows potential as a new treatment
for eumycetoma.
Materials and methods
In silico modelling
The M. mycetomatis DHODH sequence was obtained by BLAST analysis
using the Aspergillus fumigatus DHODH protein sequence as a guide (EC
1.3.5.2). M. mycetomatis, A. fumigatus and Homo sapiens DHODH sequen-
ces were aligned using Clustal Omega (EMBL-EBI, UK) and formatted using
BOXSHADE (EMBnet node, Switzerland). Mitochondrial targeting sequences
of M. mycetomatis and A. fumigatus DHODH were predicted by MitoFates23
(Japan), while the transmembrane domains were predicted by Phobius24
(Stockholm Bioinformatics Centre, Sweden).
Isolates
A total of 21 M. mycetomatis isolates with different genetic25,26 and geo-
graphical backgrounds were used in this study. Among the isolates used, 14
isolates originated from Sudan, there was 1 isolate each from Algeria, Mali,
India, Chad and the Netherlands and there were 2 isolates with unknown
origin. Isolates were obtained from the Mycetoma Research Centre in
Sudan, the Swiss Tropical Institute in Switzerland and the Westerdijk Fungal
Biodiversity Institute and Erasmus Medical Centre mycetoma collection in
the Netherlands. All isolates are maintained and preserved in the Erasmus
Medical Centre’s mycetoma collection. Isolates were identified to species
level on the basis of morphology, PCR-based RFLP and sequencing of the in-
ternal transcribed spacer (ITS) regions.27
Fungal preparation
Fungal colonies were maintained on Sabouraud dextrose agar (BD
Biosciences). After 3 weeks of growth at 37C, colonies were scraped off,
sonicated at maximum power for 5 s (Soniprep 150, Beun de Ronde, The
Netherlands) and then inoculated into 50 mL Greiner tubes (Sigma–Aldrich)
containing RPMI-1640 culture medium supplemented with 0.35 g/L L-glu-
tamine and 1.94 mM MOPS. The isolates were then further incubated for
7 days at 37C. After incubation, the mycelia within were washed once with
RPMI-1640 culture medium. A fungal suspension of 69%–71% transmission
was then prepared (Novaspec II spectrophotometer) for in vitro susceptibil-
ity testing.
In vitro susceptibility testing
Susceptibility testing was carried out according to the previously described
and validated method developed for susceptibility testing using a standar-
dized hyphal inoculum.9,28 Antifungal activity of olorofim against M. myce-
tomatis was determined using the XTT assay. Efficacy of olorofim was
compared with that of itraconazole. Olorofim was dissolved in DMSO and
tested at a range of 0.004–2 mg/L at a 2-fold dilution rate. Itraconazole
was also dissolved in DMSO and tested at a range of 0.008–16 mg/L at a
2-fold dilution rate. The assay was carried out in round-bottom microtitre
plates (Greiner Bio-one, The Netherlands). Wells in the microtitre plates
were filled with different concentrations of olorofim or itraconazole and
100lL of fungal suspension. For each fungal isolate, a drug-free and a
negative control were included. The microtitre plates were then sealed and
placed at 37C for 7 days. Endpoints were determined at Day 7 and super-
natant was measured at 450 nm (Epoch 2, Biotek, USA). MICs of olorofim
and itraconazole were determined. MIC was defined as the lowest
concentration with a minimum of 80% growth reduction. With the XTT
assay, 100% reduction in viable fungal mass could not be used as an end-
point, since a number of strains had pigments that influenced the colour in-
tensity.9,28 MIC50 and MIC90 were defined as the MICs that inhibited growth
of 50% and 90% of all isolates tested, respectively. All experiments were
performed in triplicate.
Olorofim and itraconazole interaction
A chequerboard microdilution assay was used to evaluate the in vitro activ-
ity between olorofim and itraconazole. Olorofim was evaluated using a
concentration ranging from 0.002 to 2 mg/L and itraconazole from 0.004 to
0.25 mg/L. The interaction between olorofim and itraconazole was ana-
lysed based on the FIC index and the interaction ratio (IR).29,30 FIC index val-
ues were calculated as follows:
FIC index ¼ FICA þ FICB ¼ ðMIC combA =MIC aloneA Þ þ ðMIC combB =MIC aloneB Þ
MIC combA and MIC
comb
B represent the concentration of drugs A and B, re-
spectively, when tested in combination and MIC aloneA and MIC
alone
B repre-
sent the concentration of drugs A and B, respectively, when acting
individually. An FIC index value of 0.5 is considered synergistic, a value of
>0.5 to 4 is considered indifferent and a value of >4 is considered antagonis-
tic.29,30 The IRs were calculated using the formula:
IR ¼ Io=Ie
Io and Ie represent the observed and expected percentage of inhibition for
a given interaction, respectively. Ie is calculated as follows:
Ie ¼ A þ B–ðAB=100Þ
A and B represent the percentage of inhibition observed for each compound
when acting alone. The interaction was considered synergistic when IR was
>1.5, indifferent when IR was between 0.5 and 1.5, and antagonistic when
IR was <0.5.30,31 The chequerboard assay was performed twice using
M. mycetomatis genome isolate MM55. Using the XTT endpoint read, MIC
was defined as the lowest concentration with a minimum of 80% growth
reduction.
Statistical analysis
MICs of olorofim and itraconazole were statistically compared using a
Mann–Whitney test. A P value of <0.05 was deemed statically significant.
Results
In silico modelling predicts that M. mycetomatis is
susceptible to olorofim
The analysis of DHODH sequences showed that the M. mycetoma-
tis DHODH homologue (accession number: KXX79707) shares
58.7% homology with that of A. fumigatus and 40.1% homology
with that of H. sapiens. When comparing the amino acid residues
that are predicted to be important in olorofim binding14 in both
A. fumigatus and M. mycetomatis DHODH, we observed a similarity
of 86% between the two species. M. mycetomatis DHODH shares
six out of seven predicted binding residues with A. fumigatus
DHODH. The amino acid that differed was Leu195, which corre-
sponded to the Met209 position in A. fumigatus (Figure 1). This is
a conservative replacement, with both amino acids having
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hydrophobic side chains, indicating that M. mycetomatis might be
susceptible to olorofim.
M. mycetomatis is highly susceptible to olorofim in vitro
As shown in Figure 2, MICs of olorofim ranged from 0.004 to
0.125 mg/L and MICs of itraconazole ranged from 0.008 to 0.25 mg/L.
M. mycetomatis is more susceptible to olorofim compared with
itraconazole. Significantly lower MICs were obtained for olorofim
(median = 0.016 mg/L) than for itraconazole (median = 0.031 mg/L)
(P = 0.047) (Table 1). For olorofim, a concentration of 0.016 mg/L
was needed to inhibit 50% of isolates and a concentration of
0.063 mg/L was needed to inhibit 90% of M. mycetomatis isolates.
For itraconazole, 0.031 and 0.125 mg/L was needed to inhibit 50%
and 90% of isolates, respectively.
Figure 1. Alignment of M. mycetomatis, A. fumigatus and human (H. sapiens) DHODH amino acid sequences. Conserved residues are highlighted in
black and similar residues are highlighted in grey. The predicted mitochondrial targeting sequences are indicated by the green lines and the predicted
transmembrane domains are indicated by the yellow lines. The blue arrows depict the amino acid residues predicted to be important for olorofim
binding in A. fumigatus DHODH15 that are identical in M. mycetomatis. The red arrow depicts the amino acid residue predicted to be important for
olorofim binding in A. fumigatus DHODH that deviates in M. mycetomatis. In A. fumigatus this amino acid is Met209, while in M. mycetomatis the amino
acid is Leu195. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
Lim et al.
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Indifferent interaction between olorofim and
itraconazole
To determine whether itraconazole and olorofim could potentially
be combined in a therapy, a chequerboard assay for olorofim and
itraconazole was performed on M. mycetomatis genome isolate
MM55. As shown in Table 1, an FIC index of 3.2 and an IR of 0.92
were obtained. Both these values indicate that olorofim and itra-
conazole are indifferent when combined.
Discussion
Despite treatment with itraconazole at 200–400 mg daily, only
25.9% of eumycetoma patients are cured and 2.8% end up with
amputation. This in turn leads to a high morbidity and dependency
on family members. Therefore, there is an urgent need to identify
novel drugs with activity against the causative agents of
eumycetoma.
Since the discovery of olorofim, several studies have been car-
ried out on the antifungal properties of olorofim, demonstrating its
effectiveness against several fungal species, notably Aspergillus
spp.19 Olorofim showed a lower MIC compared with other
drugs tested.16,18–20 To evaluate whether olorofim would be active
against M. mycetomatis, we first analysed and compared the
amino acid sequence of M. mycetomatis DHODH with that of
A. fumigatus. A homology of 58.7% was determined between the
two DHODH sequences. Furthermore, six out of seven amino acids
predicted by Oliver et al.14 to be important in olorofim binding were
shared. The single remaining amino acid, Met209 in the A. fumiga-
tus DHODH amino acid sequence, was replaced by Leu195 in
M. mycetomatis. Apparently this substitution did not affect the
susceptibility to olorofim as we demonstrated that M. mycetomatis
is indeed susceptible to olorofim with MICs ranging from 0.004
to 0.125 mg/L. Oliver et al.14 successfully created a mutant
Candida albicans DHODH that became susceptible to olorofim by
replacing Phe162 and Val171 (equivalent to Val200 and Met209 in
A. fumigatus) with Val162 and Met171. This indicated that these two
residues at their respective positions in each species were import-
ant for olorofim binding and subsequent inhibition of DHODH.
However, as for the two residues in M. mycetomatis, the presence
of Leu195 (Met209 in A. fumigatus) at the latter position apparently
did not impair the binding of olorofim to DHODH. Since the differ-
ence in the latter amino acid residue between M. mycetomatis and
A. fumigatus did not affect susceptibility to olorofim, taking these
data together, the resistance of C. albicans to olorofim is most like-
ly due to the difference in the former of the two residues (position
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Figure 2. In vitro activities of olorofim and itraconazole against 21 M. mycetomatis isolates, represented by MICs.
Table 1. In vitro susceptibility to olorofim and itraconazole, and the
interaction of the combined drugs
Olorofim Itraconazole Combined
MIC, median (mg/L) 0.016 0.031 —
MIC, range (mg/L) 0.004–0.125 0.008–0.25 —
MIC50 (mg/L) 0.016 0.031 —
MIC90 (mg/L) 0.063 0.125 —
MIC for M. mycetomatis
isolate MM55 (mg/L)
0.063 0.063 —
FIC index for
M. mycetomatis
isolate MM55
— — 3.2 (indifferent)
IR for M. mycetomatis
isolate MM55
— — 0.91 (indifferent)
—, not applicable.
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162 in C. albicans, 200 in A. fumigatus and 186 in M. mycetomatis).
As indicated by Oliver et al.,14 there must also be other important
differences in DHODH between these species and more studies are
needed to understand the importance of the amino acids involved
in olorofim binding.
Olorofim is currently in a Phase II study (ClinicalTrials.gov identi-
fier NCT03583164) for treatment of invasive fungal infections
caused by Scedosporium spp., Aspergillus spp. and other resistant
fungi in patients lacking suitable alternative treatment options.
This study will provide a good understanding of the dosage and
the efficacy of olorofim in patients, which might also be applicable
for mycetoma patients. However, for actinomycetoma, the bacter-
ial form of mycetoma, it was discovered that patients were more
responsive to combination therapy than to a single drug alone.
The combination therapy differs between countries; in Mexico and
Sudan the Welsh regimen is used and in India the Raman regimen
is used.3,32–35 Until now, combination therapy for eumycetoma
has not extensively been explored in animal models and clinical tri-
als. This is because the results of in vitro combination studies may
differ according to the methodologies used and thus cannot be
relied upon to predict the clinical effect that may be obtained.
For M. mycetomatis, hyphal fragments are exposed to the antifun-
gal agents in vitro, while in vivo it structures itself as grains.
Therefore, the efficacy of combination therapy should always be
determined both in vitro and in vivo.36 In the past, combination
therapy for eumycetoma did not seem feasible since all antifungal
agents with activity against the causative agents had the same
mode of action, which could lead to antagonism instead of syn-
ergy.37 When azoles were combined with terbinafine in vitro by
Ahmed et al.30 (2015), indifference and antagonism were noted.
The in vivo study by Eadie et al.37 (2017) demonstrated that com-
bining the drugs resulted in antagonism and treatment significant-
ly decreased larvae survival. Eadie et al.37 confirmed the discovery
of Scheven and Schwegler38 that antagonism occurs when ergos-
terol is inhibited via two different pathways. In this study, the com-
bination of olorofim and itraconazole, two drugs with different
modes of action, was studied. The components of the in vitro com-
bination of olorofim and itraconazole against M. mycetomatis
acted indifferently to each other, as no antagonism or synergy
was noted. Since olorofim and itraconazole inhibit fungal growth
via different mechanisms, this highlights the room for further
evaluation in vivo and in a clinical setting where they could be po-
tentially combined to treat eumycetoma.
In conclusion, we showed that olorofim inhibits growth of
M. mycetomatis and, although olorofim and itraconazole inhibit
fungal growth by different mechanisms, when combined they
show no antagonism or synergism. The next step will be to study
the efficacy of olorofim against M. mycetomatis in an in vivo
model.39
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